Business context and reporting period
The supplied filing is Sonim Technologies, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2022; it does not identify DNA X, Inc. Sonim sells rugged mobile phones and accessories and is expanding into tablets and consumer-durable devices. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless otherwise stated.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $20.5m | $14.4m | $45.7m | $38.6m |
| Gross profit / margin | $3.3m / 16.2% | $1.8m / 12.3% | $7.7m / 16.8% | $6.9m / 17.9% |
| Operating expenses | $5.2m | $12.5m | $20.9m | $33.2m |
| Operating loss | $(1.9)m | $(10.7)m | $(13.2)m | $(26.3)m |
| Net loss | $(1.6)m | $(10.9)m | $(13.0)m | $(26.9)m |
| Net loss per share | $(0.04) | $(1.31) | $(0.52) | $(3.72) |
- Operating cash flow was $(10.1)m for the first nine months, versus $(20.9)m a year earlier. Investing cash flow was $(0.006)m and financing cash flow was $14.4m; cash increased $4.2m to $15.5m.
- At September 30, cash was $15.5m, current assets $39.2m, and current liabilities $23.8m (current ratio approximately 1.6). Total debt was $0.184m; current lease liability was $0.204m.
- Stockholders’ equity was $20.7m. AJP’s $17.5m equity investment yielded approximately $14.4m net proceeds after costs and gave AJP approximately 52% ownership.
Material changes versus the prior comparable period
- Q3 revenue rose 42%, largely due to tablet sales developed for a third party; tablets contributed $14.2m, about 69% of quarterly revenue. Nine-month revenue increased 18%.
- Feature-phone revenue fell to $4.8m in Q3 from $11.4m; smartphone revenue fell to $1.5m from $2.8m as Sonim wound down a legacy smartphone ahead of new models. Tablets / other revenue rose to $14.2m from $0.2m.
- Gross profit improved in dollars, but nine-month gross margin declined to 16.8% from 17.9%, with management citing lower tablet margins.
- Lower R&D, sales and marketing, and legal expenses materially narrowed losses. Q3 R&D was reported as a $0.135m credit, including a $1.05m out-of-period adjustment for software costs capitalized in Q3 that should have been capitalized in Q2. Excluding that adjustment, Q3 R&D was approximately $0.9m.
- Results include a $0.730m gain on lease termination and a $0.130m loss on asset sale. Q3 general and administrative expense included approximately $1.2m severance accruals and $0.4m accelerated RSU vesting related to the AJP change of control.
Outlook, risks, contingencies and unusual items
- Management expected to launch a new 5G rugged smartphone in Q4 2022 and plans to expand into the consumer-durable market. The filing provides no numerical revenue or earnings guidance; the launch and growth plans are forward-looking and not assured.
- The company disclosed substantial doubt about its ability to continue as a going concern for at least one year after issuance. It may need additional funding for product development and marketing; management was evaluating financing alternatives, with no assurance funding would be available on favorable terms or at all.
- Customer and channel concentration is significant: one customer represented 68% of Q3 revenue; two customers each represented 30% of nine-month revenue. Channel partner orders generally lack firm minimum purchase commitments. Third-party manufacturers and suppliers are important to operations.
- Noncancelable component purchase commitments were approximately $9.4m; outsourced design commitments were $1.25m. Royalties were less than 5% of unit-related revenue and agreements expire between 2022 and 2026.
- Sonim reported Nasdaq minimum-bid-price noncompliance and said stockholders approved a possible 2-for-1 to 15-for-1 reverse split in October 2022; the Board retained discretion whether and when to implement it. The company also said low public float restricts shelf-registration sales to approximately $3.1m per 12 months while float remains below $75m.
- Disclosure controls were deemed ineffective. A material weakness involving IT general controls remained under remediation, and a significant deficiency in identifying software costs for capitalization prompted a new control planned for Q4.
- An SEC formal investigation concerning 2018–2019 events remained ongoing, and the company could not predict its outcome or impact. A separate derivative action was dismissed with prejudice in April 2022. Management said other ordinary-course litigation was not expected to have a material adverse effect.
Important facts for investors to verify
- Confirm this is the intended issuer: the filing names Sonim Technologies, Inc. (SONM), not DNA X, Inc.
- Reconcile reported common-share counts: the balance sheet states 40,637,828 shares at September 30, while the equity statement states 40,657,828; the filing reports 40,837,203 shares outstanding at October 31.
- Track cash burn, access to additional financing, and progress toward resolving the stated going-concern doubt.
- Assess whether the Q4 smartphone launch and tablet/customer demand generate adequate sales and margins, given concentration and the absence of firm minimum orders.
- Monitor Nasdaq listing compliance, any reverse-split action, the SEC investigation, and remediation of the material weakness and software-cost control deficiency.